Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
Go back to Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 115.71 -1.22 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $116.93 | 52 Week High | $118.49 | |||
| Open | $116.75 | 52 Week Low | $55.00 | |||
| Day High | $116.87 | P/E | N/A | |||
| Day Low | $115.12 | EPS | $-0.56 | |||
| Volume | 1,476,823 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1273.46 -33.23 (2.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1306.69 | 52 Week High | $88.16 | |||
| Open | $1304.15 | 52 Week Low | $67.88 | |||
| Day High | $1307.92 | P/E | 294.78 | |||
| Day Low | $1257.62 | EPS | $4.32 | |||
| Volume | 2,277,291 | |||||



